Anthony S. Gibney net worth and biography

Anthony Gibney Biography and Net Worth

Insider of Aura Biosciences

Tony Gibney is Chief Financial and Business Officer at Aura. Mr. Gibney is an experienced biotechnology leader and former investment banker who brings over 30 years of experience dedicated to leading and advising biotechnology companies across their businesses, including corporate strategy, business development, finance and investor relations, among others. Following his investment banking career, he has worked as Chief Business Officer at Achillion Pharmaceuticals, Inc. and Iveric Bio, Inc. and as Chief Business and Financial Officer at Fog Pharmaceuticals, Inc.

What is Anthony S. Gibney's net worth?: The estimated net worth of Anthony S. Gibney is at least $367.22 thousand as of May 16th, 2025. Mr. Gibney owns 56,933 shares of Aura Biosciences stock worth more than $367,218 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Gibney may own. Learn More about Anthony S. Gibney's net worth.
How do I contact Anthony S. Gibney?: The corporate mailing address for Mr. Gibney and other Aura Biosciences executives is , , . Aura Biosciences can also be reached via phone at 617-500-8864 and via email at [email protected]. Learn More on Anthony S. Gibney's contact information.
Has Anthony S. Gibney been buying or selling shares of Aura Biosciences?: Anthony S. Gibney has not been actively trading shares of Aura Biosciences over the course of the past ninety days. Most recently, Anthony S. Gibney sold 1,519 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $5.15, for a transaction totalling $7,822.85. Following the completion of the sale, the insider now directly owns 56,933 shares of the company's stock, valued at $293,204.95. Learn More on Anthony S. Gibney's trading history.
Who are Aura Biosciences' active insiders?: Aura Biosciences' insider roster includes Elisabet de los Pinos (Insider), Amy Elazzouzi (SVP), Anthony Gibney (Insider), Janet Hopkins (Chief Medical Officer and President of Research & Development), David Johnson (Director), Conor Kilroy (Insider), and Mark Plavsic (CTO). Learn More on Aura Biosciences' active insiders.
Are insiders buying or selling shares of Aura Biosciences?: In the last twelve months, Aura Biosciences insiders bought shares 2 times. They purchased a total of 70,000 shares worth more than $343,000.00. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 79,568 shares worth more than $514,201.11. The most recent insider tranaction occured on November, 17th when insider Janet Jill Hopkins sold 17,109 shares worth more than $92,730.78. Insiders at Aura Biosciences own 6.3% of the company. Learn More about insider trades at Aura Biosciences.
Information on this page was last updated on 11/17/2025.

Anthony S. Gibney Insider Trading History at Aura Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/16/2025	Buy	50,000	$4.90	$245,000.00	58,452
5/16/2025	Sell	1,519	$5.15	$7,822.85	56,933

Anthony S. Gibney Buying and Selling Activity at Aura Biosciences

Aura Biosciences Company Overview

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $6.45

$6.21

$6.53

50 Day Range

MA: $5.92

$5.35

$6.61

2 Week Range

Now: $6.45

$4.34

$9.14

Volume

117,755 shs

Average Volume

200,153 shs

Market Capitalization

$409.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44